1. Home
  2. ATOS vs BDSX Comparison

ATOS vs BDSX Comparison

Compare ATOS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • BDSX
  • Stock Information
  • Founded
  • ATOS 2009
  • BDSX 2005
  • Country
  • ATOS United States
  • BDSX United States
  • Employees
  • ATOS N/A
  • BDSX N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • BDSX Precision Instruments
  • Sector
  • ATOS Health Care
  • BDSX Health Care
  • Exchange
  • ATOS Nasdaq
  • BDSX Nasdaq
  • Market Cap
  • ATOS 96.8M
  • BDSX 115.4M
  • IPO Year
  • ATOS 2012
  • BDSX 2020
  • Fundamental
  • Price
  • ATOS $0.65
  • BDSX $0.61
  • Analyst Decision
  • ATOS Strong Buy
  • BDSX Strong Buy
  • Analyst Count
  • ATOS 3
  • BDSX 3
  • Target Price
  • ATOS $7.00
  • BDSX $2.93
  • AVG Volume (30 Days)
  • ATOS 520.3K
  • BDSX 276.1K
  • Earning Date
  • ATOS 03-25-2025
  • BDSX 05-07-2025
  • Dividend Yield
  • ATOS N/A
  • BDSX N/A
  • EPS Growth
  • ATOS N/A
  • BDSX N/A
  • EPS
  • ATOS N/A
  • BDSX N/A
  • Revenue
  • ATOS N/A
  • BDSX $71,323,000.00
  • Revenue This Year
  • ATOS N/A
  • BDSX $32.90
  • Revenue Next Year
  • ATOS N/A
  • BDSX $24.65
  • P/E Ratio
  • ATOS N/A
  • BDSX N/A
  • Revenue Growth
  • ATOS N/A
  • BDSX 45.30
  • 52 Week Low
  • ATOS $0.65
  • BDSX $0.59
  • 52 Week High
  • ATOS $2.31
  • BDSX $2.04
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 31.82
  • BDSX 33.15
  • Support Level
  • ATOS $0.66
  • BDSX $0.63
  • Resistance Level
  • ATOS $0.71
  • BDSX $0.78
  • Average True Range (ATR)
  • ATOS 0.04
  • BDSX 0.07
  • MACD
  • ATOS -0.00
  • BDSX -0.01
  • Stochastic Oscillator
  • ATOS 0.00
  • BDSX 9.13

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: